-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2025-522012-16-00
4
2026-03-13
Breast Cancer
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2024-515023-11-00
5
2026-01-22
Advanced Clear Cell Renal Cell Carcinoma
-
2022-501562-22-01
4
2026-01-05
Triple-negative breast cancer (TNBC) patients at high risk of relapse
-
2025-521128-31-00
9
2025-12-18
Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
-
2023-510304-53-00
10
2025-12-16
Multiple sclerosis
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-516625-31-00
3
2025-11-25
Advanced Solid Tumor
-
2024-520029-35-01
4
2025-11-17
ADVANCED BILIARY TRACT CARCINOMA
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-517316-29-00
4
2025-11-07
Unresectable stage III Non-Small Cell Lung Cancer
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2025-520694-39-00
4
2025-10-24
Metastatic or locally advanced irresectable (stage IV) gastric cancer
-
2024-514912-28-00
10
2025-10-22
Patients with hepatocellular carcinoma with high tumor burden.
-
2025-522656-68-00
6
2025-10-15
Metastatic breast cancers
-
2023-510558-18-00
4
2025-10-13
locally advanced head and neck squamous cell carcinoma
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer